Shares of Latigo Biotherapeutics, Inc. (NASDAQ:LTGO – Get Free Report) have earned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $52.25.
Several brokerages have issued reports on LTGO. Wall Street Zen raised Latigo Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Leerink Partners started coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued an “outperform” rating and a $36.00 price objective for the company. The Goldman Sachs Group initiated coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $73.00 price objective on the stock. Guggenheim began coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 target price for the company.
Read Our Latest Research Report on Latigo Biotherapeutics
Latigo Biotherapeutics Stock Down 0.1%
Shares of LTGO opened at $13.33 on Wednesday. Latigo Biotherapeutics has a 12-month low of $10.24 and a 12-month high of $25.93. The firm’s 50-day simple moving average is $17.56.
Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.55) earnings per share (EPS) for the quarter.
About Latigo Biotherapeutics
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid medicines for pain. Its research focuses on voltage-gated sodium channels, which play a role in transmitting pain signals. The company’s pipeline includes LTG-001, an oral, selective Nav1.8 inhibitor being developed for acute pain, along with additional investigational programs targeting pain conditions. Latigo’s work is aimed at providing alternatives to opioid-based pain treatment. Its product candidates are investigational and have not been established as safe or effective for any use.
Further Reading
- Five stocks we like better than Latigo Biotherapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Latigo Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Latigo Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
